Associated Papers
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Base editing screens define the genetic landscape of cancer drug resistance mechanisms.
Coelho MA et al.
Nature Genetics, 2024
Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S et al.
Molecular Cancer Therapeutics, 2023
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
McGinnis LM et al.
The American Journal of Surgical Pathology, 2018
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM et al.
Molecular Cancer Research : Mcr, 2017
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Burgess MR et al.
Cell, 2017
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Smida M et al.
Nature Communications, 2016
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Oddo D et al.
Cancer Research, 2016
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ et al.
The Journal of Clinical Investigation, 2013
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G et al.
Molecular Cancer Therapeutics, 2012
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009
Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.
Delaney AM et al.
Molecular and Cellular Biology, 2002